Cinzia Perrino, Gabriele G. Schiattarella, Fabio Magliulo, Federica Ilardi, Giuseppe Carotenuto, Giuseppe Gargiulo, Federica Serino, Marco Ferrone, Fernando Scudiero, Andreina Carbone, Bruno Trimarco and Giovanni Esposito Pages 106 - 116 ( 11 )
In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threatening drug reactions. Among these, cardiac toxic effects have recently gained particular attention. The term cardiotoxicity includes many possible pathological manifestations, but the most frequent is the reduction in cardiac function, potentially leading to heart failure and death. Importantly, the development of cardiac dysfunction may occur immediately after drug administration, or after years. The purpose of this review is to discuss the clinical features of cardiotoxicity, its molecular basis and novel possible strategies to reduce the likelihood of serious cardiac complications.
Anthracyclines, anti-neoplastic drugs, cancer, cardiotoxicity, chemotherapy, cyclophosphamide, heart failure, fluoropirimidines, oxidative stress, Trastuzumab, taxanes.
Division of Cardiology, Department of Clinical Medicine, Cardiovascular and Immunological Sciences, Federico II University, Via Pansini 5, 80131 Naples, Italy.